# CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

> **NCT05685602** · PHASE1 · SUSPENDED · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Ductal Adenocarcinoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Emavusertib
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05685602
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-06-12
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 43 (ESTIMATED)
- **Why stopped:** Drug Supply Issues
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05685602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05685602, "CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05685602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*